Your session is about to expire
← Back to Search
VTAMA (tapinarof) cream, 1% for Psoriasis
Study Summary
This trial tests a new cream for adults with psoriasis on their head and neck, to see how safe and effective it is.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a type of psoriasis that is different from plaque psoriasis.You have received UV light therapy or spent a lot of time in the sun or tanning beds in the past 4 weeks.You have been diagnosed with plaque psoriasis, including lesions on your head and neck, and your condition has been stable for at least 3 months before the study.
- Group 1: VTAMA (tapinarof) cream, 1%
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many sites are actively conducting this trial?
"The existing 10 sites participating in this trial are located across the country, including Chicago, Rockville and Auburn Hills. Prospective participants should select a location nearby to reduce travel obligations when enrolling."
Has recruitment for this trial commenced?
"According to clinicaltrials.gov, the given medical trial is actively recruiting participants - it was initially posted on March 13th 2023 and last updated April 25th of the same year."
What is the aggregate number of individuals partaking in this investigation?
"Affirmative, according to the information posted on clinicaltrials.gov, this research is actively seeking patient involvement. The trial was initially published on March 13th 2023 and most recently updated April 25th of the same year. 30 individuals need to be recruited from 10 sites for successful completion."
Has the United States Food and Drug Administration sanctioned VTAMA (tapinarof) cream, 1%?
"There is evidence to support the safety and efficacy of tapinarof cream, which has been approved for use in a Phase 4 trial. Thus, our team at Power ranked it as 3 on our scale from 1-3."
Share this study with friends
Copy Link
Messenger